These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 35113805)

  • 21. Altered activity of 11beta-hydroxysteroid dehydrogenase types 1 and 2 in skeletal muscle confers metabolic protection in subjects with type 2 diabetes.
    Jang C; Obeyesekere VR; Dilley RJ; Krozowski Z; Inder WJ; Alford FP
    J Clin Endocrinol Metab; 2007 Aug; 92(8):3314-20. PubMed ID: 17519316
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of a human blood biomarker of pharmacological 11β-hydroxysteroid dehydrogenase 1 inhibition.
    Gómez C; Alimajstorovic Z; Othonos N; Winter DV; White S; Lavery GG; Tomlinson JW; Sinclair AJ; Odermatt A
    Br J Pharmacol; 2024 Mar; 181(5):698-711. PubMed ID: 37740611
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Poorly designed research does not help clarify the role of hyperbaric oxygen in the treatment of chronic diabetic foot ulcers.
    Mutluoglu M; Uzun G; Bennett M; Germonpré P; Smart D; Mathieu D
    Diving Hyperb Med; 2016 Sep; 46(3):133-134. PubMed ID: 27723012
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of corticosteroids in skin physiology and therapeutic potential of an 11β-HSD1 inhibitor: A review.
    Hall L; Hart R
    Int J Dermatol; 2024 Apr; 63(4):443-454. PubMed ID: 38146184
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of Cold Atmospheric Plasma Therapy vs Standard Therapy Placebo on Wound Healing in Patients With Diabetic Foot Ulcers: A Randomized Clinical Trial.
    Stratmann B; Costea TC; Nolte C; Hiller J; Schmidt J; Reindel J; Masur K; Motz W; Timm J; Kerner W; Tschoepe D
    JAMA Netw Open; 2020 Jul; 3(7):e2010411. PubMed ID: 32672829
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 11beta-hydroxysteroid dehydrogenase type 1 inhibitors as promising therapeutic drugs for diabetes: status and development.
    Ge R; Huang Y; Liang G; Li X
    Curr Med Chem; 2010; 17(5):412-22. PubMed ID: 20015040
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Continuous inhibition of 11β-hydroxysteroid dehydrogenase type I in adipose tissue leads to tachyphylaxis in humans and rats but not in mice.
    Morentin Gutierrez P; Gyte A; deSchoolmeester J; Ceuppens P; Swales J; Stacey C; Eriksson JW; Sjöstrand M; Nilsson C; Leighton B
    Br J Pharmacol; 2015 Oct; 172(20):4806-16. PubMed ID: 26218540
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Selection and early clinical evaluation of the brain-penetrant 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor UE2343 (Xanamem™).
    Webster SP; McBride A; Binnie M; Sooy K; Seckl JR; Andrew R; Pallin TD; Hunt HJ; Perrior TR; Ruffles VS; Ketelbey JW; Boyd A; Walker BR
    Br J Pharmacol; 2017 Mar; 174(5):396-408. PubMed ID: 28012176
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of chronic diabetic lower leg ulcers with activated protein C: a randomised placebo-controlled, double-blind pilot clinical trial.
    Whitmont K; McKelvey KJ; Fulcher G; Reid I; March L; Xue M; Cooper A; Jackson CJ
    Int Wound J; 2015 Aug; 12(4):422-7. PubMed ID: 23848141
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of dalteparin on healing of chronic foot ulcers in diabetic patients with peripheral arterial occlusive disease: a prospective, randomized, double-blind, placebo-controlled study.
    Kalani M; Apelqvist J; Blombäck M; Brismar K; Eliasson B; Eriksson JW; Fagrell B; Hamsten A; Torffvit O; Jörneskog G
    Diabetes Care; 2003 Sep; 26(9):2575-80. PubMed ID: 12941721
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Skin 11β-hydroxysteroid dehydrogenase type 1 enzyme expression regulates burn wound healing and can be targeted to modify scar characteristics.
    Tsai KH; Shi H; Parungao RJ; Naficy S; Ding X; Ding X; Hew JJ; Wang X; Chrzanowski W; Lavery GG; Li Z; Issler-Fisher AC; Chen J; Tan Q; Maitz PK; Cooper MS; Wang Y
    Burns Trauma; 2023; 11():tkac052. PubMed ID: 36694861
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of 11β-HSD1 with RO5093151 for non-alcoholic fatty liver disease: a multicentre, randomised, double-blind, placebo-controlled trial.
    Stefan N; Ramsauer M; Jordan P; Nowotny B; Kantartzis K; Machann J; Hwang JH; Nowotny P; Kahl S; Harreiter J; Hornemann S; Sanyal AJ; Stewart PM; Pfeiffer AF; Kautzky-Willer A; Roden M; Häring HU; Fürst-Recktenwald S
    Lancet Diabetes Endocrinol; 2014 May; 2(5):406-16. PubMed ID: 24795254
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased Expression of 11β-Hydroxysteroid Dehydrogenase Type 1 Contributes to Epidermal Permeability Barrier Dysfunction in Aged Skin.
    Kim BJ; Lee NR; Lee CH; Lee YB; Choe SJ; Lee S; Hwang HJ; Kim E; Lavery GG; Shin KO; Park K; Choi EH
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34072239
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increased whole-body and sustained liver cortisol regeneration by 11beta-hydroxysteroid dehydrogenase type 1 in obese men with type 2 diabetes provides a target for enzyme inhibition.
    Stimson RH; Andrew R; McAvoy NC; Tripathi D; Hayes PC; Walker BR
    Diabetes; 2011 Mar; 60(3):720-5. PubMed ID: 21266326
    [TBL] [Abstract][Full Text] [Related]  

  • 35. UVB induces epidermal 11β-hydroxysteroid dehydrogenase type 1 activity in vivo.
    Tiganescu A; Hupe M; Jiang YJ; Celli A; Uchida Y; Mauro TM; Bikle DD; Elias PM; Holleran WM
    Exp Dermatol; 2015 May; 24(5):370-6. PubMed ID: 25739654
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety, efficacy and weight effect of two 11β-HSD1 inhibitors in metformin-treated patients with type 2 diabetes.
    Heise T; Morrow L; Hompesch M; Häring HU; Kapitza C; Abt M; Ramsauer M; Magnone MC; Fuerst-Recktenwald S
    Diabetes Obes Metab; 2014 Nov; 16(11):1070-7. PubMed ID: 24828020
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Bio-inductive effects of inorganic elements on skin wound healing].
    Zhou LS; Liao ZJ; Zhang Q; Luo M; Lu G; Zhang W
    Zhonghua Shao Shang Za Zhi; 2005 Oct; 21(5):363-6. PubMed ID: 16383040
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of PDRN, an adenosine receptor A2A agonist, on the healing of chronic diabetic foot ulcers: results of a clinical trial.
    Squadrito F; Bitto A; Altavilla D; Arcoraci V; De Caridi G; De Feo ME; Corrao S; Pallio G; Sterrantino C; Minutoli L; Saitta A; Vaccaro M; Cucinotta D
    J Clin Endocrinol Metab; 2014 May; 99(5):E746-53. PubMed ID: 24483158
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nutritional interventions for treating foot ulcers in people with diabetes.
    Moore ZE; Corcoran MA; Patton D
    Cochrane Database Syst Rev; 2020 Jul; 7(7):CD011378. PubMed ID: 32677037
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 11β-hydroxysteroid dehydrogenase 1 specific inhibitor increased dermal collagen content and promotes fibroblast proliferation.
    Terao M; Tani M; Itoi S; Yoshimura T; Hamasaki T; Murota H; Katayama I
    PLoS One; 2014; 9(3):e93051. PubMed ID: 24667799
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.